Hydrochlorothiazide

Generic Name
Hydrochlorothiazide
Brand Names
Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
Drug Type
Small Molecule
Chemical Formula
C7H8ClN3O4S2
CAS Number
58-93-5
Unique Ingredient Identifier
0J48LPH2TH
Background

Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II rec...

Indication

Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions
Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
Associated Therapies
-
Clinical Trials
Related News

Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients

First Posted Date
2013-03-27
Last Posted Date
2015-10-23
Lead Sponsor
Yining Huang
Target Recruit Count
1200
Registration Number
NCT01819441
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

Early Phase 1
Terminated
Conditions
Proteinuria
Hypertension
Type II Diabetes
Interventions
Drug: Amiloride
Drug: HCTZ
First Posted Date
2013-03-05
Last Posted Date
2018-05-11
Lead Sponsor
University of New Mexico
Target Recruit Count
9
Registration Number
NCT01804777
Locations
🇺🇸

University of New Mexico Hospital; Clinical & Translational Science Center, Albuquerque, New Mexico, United States

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide

First Posted Date
2013-01-14
Last Posted Date
2013-01-15
Lead Sponsor
Damanhour University
Target Recruit Count
24
Registration Number
NCT01767259
Locations
🇪🇬

Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt

Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)

First Posted Date
2013-01-14
Last Posted Date
2013-01-14
Lead Sponsor
Damanhour University
Target Recruit Count
24
Registration Number
NCT01767298

EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network

Phase 4
Withdrawn
Conditions
Hypertension
Interventions
Drug: Chlorthalidone
Drug: Hydrochlorothiazide
First Posted Date
2012-12-12
Last Posted Date
2017-08-18
Lead Sponsor
Johns Hopkins University
Registration Number
NCT01748123
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions

Not Applicable
Completed
Conditions
Hypertension
Interventions
Drug: Irbesartan and Hydrochlorothiazide
Drug: Avalide
First Posted Date
2012-10-23
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
37
Registration Number
NCT01712139
Locations
🇺🇸

Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

Not Applicable
Completed
Conditions
Hypertension
Interventions
Drug: Irbesartan and Hydrochlorothiazide
Drug: Avalide
First Posted Date
2012-10-23
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
40
Registration Number
NCT01712126
Locations
🇺🇸

Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

First Posted Date
2012-09-25
Last Posted Date
2016-05-04
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
454
Registration Number
NCT01692301
Locations
🇨🇳

Novartis Investigative Site, Taipei, Taiwan

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

First Posted Date
2012-08-07
Last Posted Date
2015-08-27
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
17
Registration Number
NCT01658657
Locations
🇺🇸

UNC Chapel Hill, Chapel Hill, North Carolina, United States

Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure

Phase 3
Completed
Conditions
Heart Failure
Interventions
Drug: Placebo
Drug: hydrochlorothiazide
First Posted Date
2012-07-24
Last Posted Date
2022-10-04
Lead Sponsor
Spanish Society of Internal Medicine
Target Recruit Count
232
Registration Number
NCT01647932
Locations
🇪🇸

Internal Medicine Service, Hospital d'Olot (Girona), Olot, Girona, Spain

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy